Multiplicity of effectors of the cardioprotective agent, diazoxide.
about
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Cardiovascular KATP channels and advanced agingInhibitory and excitatory neuromodulation by hydrogen peroxide: translating energetics to informationNonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Direct activation of β-cell KATP channels with a novel xanthine derivative.Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat.Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats.Mitochondrial mechanisms in cerebral vascular control: shared signaling pathways with preconditioning.Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.Role of ATP-dependent K channels in the effects of erythropoietin in renal ischaemia injuryKATP Channels in the Cardiovascular System.Plasticity of sarcolemmal KATP channel surface expression: relevance during ischemia and ischemic preconditioning.Priming adult stem cells by hypoxic pretreatments for applications in regenerative medicine.Altered KATP Channel Subunits Expression and Vascular Reactivity in Spontaneously Hypertensive Rats With AgeMitochondrial channels: ion fluxes and more.Inflammation and tuberculosis: host-directed therapies.Mitochondrial involvement in myocyte death and heart failure.Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.The role of succinate and ROS in reperfusion injury - A critical appraisal.Mitochondria, Bioenergetics and Excitotoxicity: New Therapeutic Targets in Perinatal Brain InjuryThe ATP-sensitive K channel is seizure protective and required for effective dietary therapy in a model of mitochondrial encephalomyopathy.Differential actions of AMP kinase on ATP-sensitive K+ currents in ventral tegmental area and substantia nigra zona compacta neurons.Role of Mitochondria in Cerebral Vascular Function: Energy Production, Cellular Protection, and Regulation of Vascular Tone.Diazoxide Improves Mitochondrial Connexin 43 Expression in a Mouse Model of Doxorubicin-Induced Cardiotoxicity.Diazoxide preconditioning of endothelial progenitor cells improves their ability to repair the infarcted myocardium.
P2860
Q26742059-1D57FDD0-DDFD-4AAF-9CCE-D2001283DB31Q28076393-A865CA5F-CA12-4898-80DF-9A4B5C63D441Q28082229-7B31353C-9F91-4E21-8BC6-D47C281CC0CCQ30583012-AFB1334B-12E4-486F-92B5-731CE927B665Q33584589-38D30BE0-AD72-4DA3-A3CE-C5CA63CAC8EDQ33712631-1F11B571-385F-4F0A-B692-92C27290F40CQ33898386-EB67DCD5-A2AB-4A83-819D-57045CC75D8AQ34062807-3BDCD496-56E5-4CAB-984D-6269DA732409Q34111653-9E43B988-A5C7-469E-A028-A0F5A7B303DDQ35148462-30868AC6-56E3-4BDE-BD80-0DCADC49D255Q35917813-6E03433C-9DC5-4719-A779-2AD9A9B8E23DQ36422478-8ED4938D-A8CA-44C1-BEDA-EC3B3559BBCAQ37071917-DB26DD94-E7F8-4B1D-95FC-2CC81F9CEF22Q37153287-3F8A45DD-AFD8-4547-B5D3-7D347B7EE2BCQ37164619-49112FD2-DD00-4043-8D33-EF3139B7D985Q38201407-59BA8C99-579D-4822-B547-B22B10D7DEEEQ38203352-22224A76-0272-4212-B950-11EE809B443DQ38737214-CC4F0097-5524-4693-869B-1B3DE6BC4BADQ39392990-A7F629EF-7AB5-449C-BD40-B17A2317E157Q39423100-DC694DCA-ECFB-40D9-BABA-2FAEC98B6CF2Q40987303-C8B44EFF-0854-47EF-8E4C-A4D36E815BB6Q45360261-ED7A4310-9971-44C0-AF76-7914551680D6Q47618664-6A292CD3-EB80-47AB-8D79-25540784ED1FQ48653884-04A07DA3-2585-4F66-AF41-4B8AF51EF3A2Q51742732-BCD13942-75BD-40FD-BB19-34BCC6378657Q53484210-BCE28EE8-0654-4A8D-B9B9-09721870231A
P2860
Multiplicity of effectors of the cardioprotective agent, diazoxide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@en
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@nl
type
label
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@en
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@nl
prefLabel
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@en
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@nl
P2860
P1476
Multiplicity of effectors of the cardioprotective agent, diazoxide.
@en
P2093
William A Coetzee
P2860
P304
P356
10.1016/J.PHARMTHERA.2013.06.007
P577
2013-06-19T00:00:00Z